Preview

Гематология и трансфузиология

Расширенный поиск

Значение минимальной остаточной болезни при хроническом лимфолейкозе в эру таргетных лекарственных препаратов

https://doi.org/10.18821/0234-5730/2016-61-4-190-196

Полный текст:

Аннотация

Полная ремиссия (ПР) и длительная беспрогрессивная выживаемость (БПВ) могут быть достигнуты уже после первой линии химиоиммунотерапии у большинства больных хроническим лимфолейкозом (ХЛЛ). Тем не менее в костном мозге значительного числа больных с ПР заболевания иммунологическими и генетическими методами выявляют некоторое количество опухолевых клеток (более 1 на 10 000 нормальных клеток), которые определяют суть минимальной остаточной болезни (МОБ). МОБ-негативный статус больного ассоциируется с длительной БПВ и общей выживаемостью и является единственным благоприятным прогностическим фактором, определяемым после терапии. Появление таргетных препаратов терапии ХЛЛ (ибрутиниб, иделалисиб, венетоклакс), имеющих высокую эффективность и низкий профиль токсичности, позволяет надеяться на увеличение числа МОБ-негативных ремиссий, а изменение тактики лечения – на решение проблемы контроля за остаточным опухолевым клоном.

Об авторах

А. Ю. Кувшинов
ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии» ФМБА России
Россия

Кувшинов  Алексей  Юрьевич,  младший  научный  сотрудник  научной лаборатории

191024, г. Санкт-Петербург



С. В. Волошин
ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии» ФМБА России
Россия
191024, г. Санкт-Петербург


И. С. Мартынкевич
ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии» ФМБА России
Россия
191024, г. Санкт-Петербург


Е. В. Клеина
ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии» ФМБА России
Россия
191024, г. Санкт-Петербург


А. В. Чечеткин
ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии» ФМБА России
Россия
191024, г. Санкт-Петербург


Список литературы

1. Bosch F., Ferrer A., Villamor N., González M., Briones J., GonzálezBarca E., et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin. Cancer Res. 2008; 14(1): 155–61. doi: 10.1158/1078-0432.CCR-07-1371.

2. Robertson L.E., Huh Y.O., Butler J.J., Pugh W.C., Hirsch-Ginsberg C., Stass S., et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood. 1992; 80(1): 29–36.

3. O’Brien S.M., Kantarjian H.M., Cortes J., Beran M., Koller C.A., Giles F.J., et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J. Clin. Oncol. 2001; 19(5): 1414–20.

4. Eichhorst B.F., Busch R., Hopfinger G., Pasold R., Hensel M., Steinbrecher C., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006; 107(3): 885–91. doi: 10.1182/blood-2005-06-2395.

5. Flinn I.W., Neuberg D.S., Grever M.R., Dewald G.W., Bennett J.M., Paietta E.M., et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol. 2007; 25(7): 793–8. doi: 10.1200/JCO.2006.08.0762.

6. Tam C.S., O’Brien S., Wierda W., Kantarjian H., Wen S., Do K.A., et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008; 112(4): 975–80. doi: 10.1182/blood-2008-02-140582.

7. Keating M.J., O’Brien S., Albitar M., Lerner S., Plunkett W., Giles F., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 2005; 23(18): 4079–88. doi: 10.1200/jco.2005.12.051.

8. Hallek M., Fingerle-Rowson G., Fink A.M., Busch R.M., Mayer J., Hensel M., et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progressionfree survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood. 2008; 112(11): Abstract 325.

9. Böttcher S., Ritgen M., Fischer K., Stilgenbauer S., Busch R.M., FingerleRowson G., et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J. Clin. Oncol. 2012; 30(9): 980–8. doi: 10.1200/JCO.2011.36.9348.

10. Кувшинов А.Ю., Волошин С.В., Мартынкевич И.С., Клеина Е.В., Михалева М.А., Абдулкадыров К.М. Хронический лимфолейкоз: прогностическое значение минимальной остаточной болезни, возможности современных методов ее выявления и коррекции (обзор литературы). Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2016; 9(2): 191–8. doi: 10.21320/2500-2139-2016-9-2-191-198.

11. Moreno C., Villamor N., Colomer D., Esteve J., Gine E., Muntañola A., et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006; 107(11): 4563–9. doi: 10.1182/blood-2005-09-3634.

12. Kovacs G., Böttcher S., Bahlo J., Kluth S., Ritgen M., Fink A.M., et al. Value of minimal residual disease (MRD) negative status at response evaluation in chronic lymphocytic leukemia (CLL): combined analysis of two phase III studies of the German CLL Study Group (GCLLSG). Blood. 2014; 124(21): 23. http://www.bloodjournal.org/content/124/21/23?ssochecked=true.

13. Eichhorst B., Fink A.M., Busch R., Kovacs G., Maurer C., Lange E., et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 study). Blood. 2014; 124(21): 19. http://www.bloodjournal.org/content/124/21/19?sso-checked=true.

14. Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Döhner H., et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer InstituteWorking Group 1996 guidelines. Blood. 2008; 111(12): 5446–56. doi: 10.1182/blood-2007-06-093906.

15. Böttcher S., Ritgen M., Pott C., Brüggemann M., Raff T., Stilgenbauer S.,et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia. 2004; 18(10): 1637–45. doi: 10.1038/sj.leu.2403478.

16. Van Dongen J.J., Langerak A.W., Bruggemann M., Evans P.A., Hummel M., Lavender F.L., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17(12): 2257–317. doi: 10.1038/sj.leu.2403202.

17. Milligan D.W., Fernandes S., Dasgupta R., Davies F.E., Matutes E., Fegan C.D., et al. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. Blood. 2005; 105(1): 397–404. doi: 10.1182/blood-2004-01-0298.

18. Rawstron A.C., Kennedy B., Evans P.A., Davies F.E., Richards S.J., Haynes A.P., et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy.Blood. 2001; 98(1): 29–35. doi: 10.1182/blood.v98.1.29.

19. Ringelstein-Harlev S., Fineman R. Minimal Residual Disease Surveillance in Chronic Lymphocytic Leukemia by Fluorescence-Activated Cell Sorting. Rambam Maimonides Med. J. 2014; 5(4): е0027. doi: 10.5041/RMMJ.10161. http://www.rmmj.org.il/userimages/421/1/PublishFiles/446Article.pdf

20. NCCN Clinical Practice Guidelines in Oncology, Non-Hodgkin’s lymphomas, version 3.2016. https://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf.

21. Strati P., Keating M.J., Wierda W.G., Badoux X.C., Calin S., Reuben J.M., et al. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood. 2013; 122(5): 734–7. doi: 10.1182/blood-2013-04-495341.

22. Chen C.I., Paul H., Wang T., Le L.W., Dave N., Kukreti V., et al. Longterm follow-up of a phase 2 trial of single agent lenalidomide in previously untreated patients with chronic lymphocytic leukaemia. Br. J. Haematol. 2014; 165(5): 731–3. doi: 10.1111/bjh.12785.

23. Byrd J.C., Furman R.R., Coutre S.E., Flinn I.W., Burger J.A., Blum K.A., et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2013; 369(1): 32–42. doi: 10.1056/NEJMoa1215637.

24. O’Brien S., Furman R.R., Coutre S.E., Sharman J.P., Burger J.A., Blum K.A., et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol. 2014; 15(1): 48–58. doi: 10.1016/S1470-2045(13)70513-8.

25. Furman R.R., Sharman J.P., Coutre S.E., Cheson B.D., Pagel J.M., Hillmen P., et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2014; 370(11): 997–1007. doi: 10.1056/NEJMoa1315226.

26. O’Brien S., Lamanna N., Kipps T.J., Flinn I., Zelenetz A.D., Burger J.A., et al. A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. Blood. 2015; 126(25): 2686–94. doi: 10.1182/blood-2015-03-630947.

27. Brown J.R., Byrd J.C., Coutre S.E., Benson D.M., Flinn I.W., WagnerJohnston N.D., et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014; 123(22): 3390–7. doi: 10.1182/blood-2013-11-535047.

28. Goede V., Fischer K., Busch R., Engelke A., Eichhorst B., Wendtner C.M., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 2014; 370(12): 1101–10. doi: 10.1056/NEJMoa1313984.

29. Stilgenbauer S., Ilhan O.,Woszczyk D., Renner C., Mikuskova E., Böttcher r S., et al. Safety and efficacy of Obinutuzumab plus Bendamustine in previously untreated patients with chronic lymphocytic leukemia: subgroup analysis of the Green Study. Blood. 2015; 126(23): 493. http://www.bloodjournal.org/content/126/23/493?sso-checked=true.

30. Roberts A.W., Davids M.S., Pagel J.M., Kahl B.S., Puvvada S.D., Gerecitano J.F., et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2016; 374(4): 311–22. doi: 10.1056/NEJMoa1513257.

31. Ma S., Brander D.M., Seymour J.F., Kipps T.J., Barrientos J.C., Davids M.S., et al. Deep and Durable Responses Following Venetoclax (ABT-199 / GDC-0199) Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from a Phase 1b Study. Blood. 2015; 126(23): 830. http://www.bloodjournal.org/content/126/23/830?sso-checked=true.

32. Byrd J.C., Furman R.R., Coutre S.E., Burger J.A., Blum K.A., Coleman M., et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015; 125(16): 2497–506. doi:10.1182/blood-2014-10-606038.

33. FDA Approves Imbruvica to Treat Chronic Lymphocytic Leukemia. https://www.drugs.com/newdrugs/fda-approves-imbruvica-chroniclymphocytic-leukemia-4007.html

34. Byrd J.C., Brown J.R., O’Brien S., Barrientos J.C., Kay N.E., Reddy N.M., et al. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. N. Engl. J. Med. 2014; 371(3): 213–23. doi: 10.1056/NEJMoa1400376.

35. O’Brien S., Jones J.A., Couture S., Mato A.R., Hillmen P., Tam C., et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE™-17 trial. (ASH Annual Meeting Abstracts). Blood. 2014; 124(21): 327. http://www.bloodjournal.org/content/124/21/327?sso-checked=true.

36. FDA Expands Approved Use of Imbruvica for Chronic Lymphocytic Leukemia. https://www.drugs.com/newdrugs/fda-expands-approvedimbruvica-chronic-lymphocytic-leukemia-4061.html.

37. Burger J.A., Tedeschi A., Barr P.M., Robak T., Owen C., Ghia P., et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N. Engl. J. Med. 2015; 373(25): 2425–37. doi: 10.1056/NEJMoa1509388.

38. FDA Approves Imbruvica (ibrutinib) for the First-Line Treatment of Chronic Lymphocytic Leukemia. http://www.drugs.com/newdrugs/fda-approves-imbruvica-ibrutinib-first-line-chronic-lymphocyticleukemia-4353.html.

39. Fraser G., Cramer P., Demirkan F., Silva R.S., Pylypenko H., Grosicki S., et al. Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. J. Clin. Oncol. 2016; 34: Abstract 7525.

40. Maddocks K.J., Ruppert A.S., Lozanski G., Heerema N.A., Zhao W., Abruzzo L., et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015; 1(1): 80–7. doi:10.1001/jamaoncol.2014.218.

41. Jain P., Keating M., Wierda W., Estrov Z., Ferrajoli A., Jain N., et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015; 125(13): 2062–7. doi:10.1182/blood-2014-09-603670.

42. Public Workshop on Minimal Residual Disease (MRD) as a Surrogate Endpoint in Chronic Lymphocytic Leukemia (CLL). http://www.fda.gov/Drugs/NewsEvents/ucm340707.htm


Для цитирования:


Кувшинов А.Ю., Волошин С.В., Мартынкевич И.С., Клеина Е.В., Чечеткин А.В. Значение минимальной остаточной болезни при хроническом лимфолейкозе в эру таргетных лекарственных препаратов. Гематология и трансфузиология. 2016;61(4):190-196. https://doi.org/10.18821/0234-5730/2016-61-4-190-196

For citation:


Kuvshinov A.Yu., Voloshin S.V., Martynkevich I.S., Kleina E.V., Chechetkin A.V. The meaning of the minimal residual disease in chronic lymphocytic leukemia in the era of targeted drugs. Russian journal of hematology and transfusiology. 2016;61(4):190-196. (In Russ.) https://doi.org/10.18821/0234-5730/2016-61-4-190-196

Просмотров: 93


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0234-5730 (Print)
ISSN 2411-3042 (Online)